Market Research Report
Biosimilars Market Access in Psoriatic Arthritis
|Published by||Datamonitor Healthcare||Product code||498963|
|Published||Content info||24 Pages
Delivery time: 1-2 business days
|Biosimilars Market Access in Psoriatic Arthritis|
|Published: March 23, 2017||Content info: 24 Pages||
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches. Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.